Cambridge Healthtech Institute's Fourth Annual

CHO Cell Lines

( CHO细胞株 )

Enhancing Expression, Performance & Process

2018年1月10日 - 11日

 

CHO cells' rapid rise in production prominence is due to their adaptability to various culture conditions, gene plasticity, and ability in proper folding, posttranslational modifications, and glycosylation of desired proteins. Thus, advances in CHO cell lines and culture continue to significantly improve biotherapeutic production. This achievement is due to progress in engineering stable and transient cell lines, enhancing cell culture conditions and performance, as well as optimizing process development. When all are accomplished, higher-production titers and better product quality result. The CHO Cell Lines conference gathers cell line engineers, cell culture specialists and bioprocess development managers to explore the latest data, tools and strategies for improving protein expression, production, and product quality.

We invite presentation proposals on the following preliminary topics:

Cell Line Engineering

  • Sequencing the CHO Genome
  • Genome Engineering
  • Gene Synthesis
  • Transient Cell Lines
  • Stable Cell Lines
  • Cell Line Selection & Optimization

Cell Culture Conditions

  • Media Optimization
  • Process Development
  • Metabolomics
  • Expression Profiling
  • Cellular Responses to Process Conditions
  • Glycosylation
  • Cell Growth & Productivity
  • Increasing Yield
  • Increasing Titers
  • Automation
  • Regulatory Perspectives on New Technologies
  • Hurdles for Introducing New Technologies

Optimizing Bioprocesses

  • Process Conditions
  • Online Monitoring
  • Single-Use Systems
  • Strategies for Scaling Down
  • Protocols for Scaling Up
  • Cell Growth
  • Cell Harvest
  • Cell Line Serviceability

Analytics

  • Rational Study Design and Effective Use of Design of Experiment (DOE)
  • Application of DOE to Optimize Product and Process Parameters
  • Quality by Design (QbD) Approaches

Proposed presentations should focus on case studies, lessons learned and strategies for enhancing CHO cell culture and achieving higher biotherapeutic production.

All proposals are subject to review by the Scientific Advisory Committee to ensure the overall quality of the conference program. Please note that due to limited speaking slots, preference will be given to abstracts from those within pharmaceutical and biopharmaceutical companies, regulators and those from academic centers. Additionally, as per CHI policy, a select number of vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

* 活动内容有可能不事先告知作更动及调整。